Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center

Introduction: Biologic drugs have dramatically improved severe eosinophilic asthma (SEA) outcomes. Our aim was to evaluate the long-term efficacy of biological therapy in SEA in a real-life setting and to identify the predictors for switching to another biological drug in patients with poor asthma c...

Descripción completa

Detalles Bibliográficos
Autores principales: Solidoro, Paolo, Nicola, Stefania, Ridolfi, Irene, Canonica, Giorgio Walter, Blasi, Francesco, Paggiaro, Pierluigi, Heffler, Enrico, Bagnasco, Diego, Patrucco, Filippo, Ribolla, Fulvia, Bucca, Caterina, Rolla, Giovanni, Albera, Carlo, Brussino, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869384/
https://www.ncbi.nlm.nih.gov/pubmed/35203409
http://dx.doi.org/10.3390/biomedicines10020200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869384/
https://www.ncbi.nlm.nih.gov/pubmed/35203409
http://dx.doi.org/10.3390/biomedicines10020200

Ejemplares similares